NICE has recommended durvalumab for the maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation in final draft guidance, which reviewed the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for the treatment.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us